Know Cancer

or
forgot password

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer


Phase 2
N/A
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer


Inclusion Criteria:



- Subjects who were confirmed to have a response after receiving at least two courses
of weekly paclitaxel therapy and considered to need to continue the therapy by the
investigator/subinvestigator among the patients with advanced or recurrent breast
cancer who had met the selection criteria and participated in the preceding phase II
clinical study

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Adverse event

Outcome Time Frame:

Throughout the study

Safety Issue:

Yes

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

Japan: Pharmaceuticals and Medical Devices Agency

Study ID:

CA139-387

NCT ID:

NCT00971945

Start Date:

June 2005

Completion Date:

March 2008

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location